레이크우드 아메덱스 바이오LABT 주가

Lakewood-Amedex Biotherapeutics Expands Global Intellectual Property Portfolio With Issuance Of Two Patents, One Each In Australia And New Zealand Respectively

Patent portfolio now includes 71 granted patents and 28 pending patent applications, covering composition of matter, formulation, and use patentsSARASOTA, Fla., May 27, 2026 /PRNewswire/ -- Lakewood-Amedex

♻️ 재탕[424B3] 424B3 — PROSPECTUS SUPPLEMENT

[424B3] 424B3 — PROSPECTUS SUPPLEMENT

[10-Q] 분기 실적 — QUARTERLY REPORT

12 Health Care Stocks Moving In Wednesday's Intraday Session

Lakewood-Amedex Stock Falls Despite Positive Nu-3 Manufacturing Update

Lakewood-Amedex Biotherapeutics shares were trading higher Monday but have reversed lower after the company announced data for Nu-3.

Lakewood-Amedex Biotherapeutics announces positive data for the advancement of lead candidate, Nu-3

Lakewood-Amedex Biotherapeutics Inc: Lakewood-Amedex Biotherapeutics announces positive data for the advancement of lead candidate, Nu-3, in infected diabetic foot ulcers Lakewood-Amedex...

Lakewood-Amedex Biotherapeutics Reports Nu-3 Data And Completes Key Manufacturing Milestones Ahead Of Planned Phase 2 Trial For Diabetic Foot Ulcer Treatment

Key formulation, delivery and manufacturing steps completed in preparation for planned Phase 2 clinical trial

[424B4] 424B4 — PROSPECTUS

[EFFECT] EFFECT